Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild(University Hospital Schleswig-Holstein), Ulrich Keilholz(German Cancer Research Center), John M. Kirkwood(UPMC Hillman Cancer Center), Uwe Trefzer(Goethe University Frankfurt), Adil Daud(University of California, San Francisco), J. Michael White(Goethe University Frankfurt), Dirk Schadendorf(National Center for Tumor Diseases), Stephan Grabbe(Goethe University Frankfurt), Alexander M.M. Eggermont(University Medical Center Utrecht), Peter Hersey(The University of Sydney), Steven O’Day(Saint John's Health Center), Sanjiv S. Agarwala(Goethe University Frankfurt), David Hogg(University of Leeds), Christian Peschel(Technical University of Munich), Caroline Robert(Institut Gustave Roussy), Chenghua Xia(Goethe University Frankfurt), Kiran Patel(Goethe University Frankfurt), Claus Garbe(University of Tübingen), Jens Gille(Goethe University Frankfurt), René González(University of Miami)
Cited by 545
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k